AU2001263506A1 - Encapsulating a toxic core within a non-toxic region in an oral dosage form - Google Patents

Encapsulating a toxic core within a non-toxic region in an oral dosage form

Info

Publication number: AU2001263506A1
Authority: AU; Australia
Prior art keywords: toxic; dosage form; region; potent; liquid
Prior art date: 2000-05-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001263506A

Other languages

English (en)

Inventor

Michael J. Cima

Christopher M Gaylo

Donald C. Monkhouse

Francis C. Payumo

Jill K. Sherwood

Chen-Chao Wang

Jaedeok Yoo

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Massachusetts Institute of Technology

AFBS Inc

Original Assignee

Massachusetts Institute of Technology

Therics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-18

Filing date

2001-05-18

Publication date

2001-11-26

2001-05-18 Application filed by Massachusetts Institute of Technology, Therics Inc filed Critical Massachusetts Institute of Technology

2001-11-26 Publication of AU2001263506A1 publication Critical patent/AU2001263506A1/en

Status Abandoned legal-status Critical Current

Links

231100000331 toxic Toxicity 0.000 title claims abstract description 74
230000002588 toxic effect Effects 0.000 title claims abstract description 74
231100000252 nontoxic Toxicity 0.000 title claims abstract description 25
230000003000 nontoxic effect Effects 0.000 title claims abstract description 25
239000006186 oral dosage form Substances 0.000 title abstract description 33
239000007788 liquid Substances 0.000 claims abstract description 76
239000000843 powder Substances 0.000 claims abstract description 71
239000002552 dosage form Substances 0.000 claims abstract description 56
230000003389 potentiating effect Effects 0.000 claims abstract description 52
238000004519 manufacturing process Methods 0.000 claims abstract description 40
239000002245 particle Substances 0.000 claims abstract description 36
239000007787 solid Substances 0.000 claims abstract description 14
239000000725 suspension Substances 0.000 claims abstract description 14
230000007928 solubilization Effects 0.000 claims abstract description 8
238000005063 solubilization Methods 0.000 claims abstract description 8
238000010146 3D printing Methods 0.000 claims abstract description 6
239000011230 binding agent Substances 0.000 claims description 61
238000000034 method Methods 0.000 claims description 40
239000000126 substance Substances 0.000 claims description 22
239000000546 pharmaceutical excipient Substances 0.000 claims description 15
239000002775 capsule Substances 0.000 claims description 14
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
239000013590 bulk material Substances 0.000 claims description 11
239000012530 fluid Substances 0.000 claims description 11
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
229940088597 hormone Drugs 0.000 claims description 9
239000005556 hormone Substances 0.000 claims description 9
VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 7
229950009213 rubitecan Drugs 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 6
239000000499 gel Substances 0.000 claims description 6
239000002246 antineoplastic agent Substances 0.000 claims description 5
229940041181 antineoplastic drug Drugs 0.000 claims description 5
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical group C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
239000004014 plasticizer Substances 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 4
230000001070 adhesive effect Effects 0.000 claims description 4
230000001093 anti-cancer Effects 0.000 claims description 4
229940127093 camptothecin Drugs 0.000 claims description 4
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 4
229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
239000000853 adhesive Substances 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 2
238000001879 gelation Methods 0.000 claims description 2
229920001477 hydrophilic polymer Polymers 0.000 claims description 2
230000005012 migration Effects 0.000 claims description 2
238000013508 migration Methods 0.000 claims description 2
230000007480 spreading Effects 0.000 claims description 2
238000003892 spreading Methods 0.000 claims description 2
239000000375 suspending agent Substances 0.000 claims description 2
231100000086 high toxicity Toxicity 0.000 claims 2
230000003533 narcotic effect Effects 0.000 claims 2
229940035722 triiodothyronine Drugs 0.000 claims 2
229940050521 gelatin agent Drugs 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 85
229940079593 drug Drugs 0.000 abstract description 79
238000000576 coating method Methods 0.000 abstract description 17
238000002955 isolation Methods 0.000 abstract description 11
238000012377 drug delivery Methods 0.000 abstract description 3
239000000383 hazardous chemical Substances 0.000 abstract description 3
239000010410 layer Substances 0.000 description 38
230000000740 bleeding effect Effects 0.000 description 15
230000007704 transition Effects 0.000 description 15
239000011248 coating agent Substances 0.000 description 12
231100001261 hazardous Toxicity 0.000 description 9
238000007639 printing Methods 0.000 description 9
229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
230000008901 benefit Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
230000033001 locomotion Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
230000003474 anti-emetic effect Effects 0.000 description 4
239000002111 antiemetic agent Substances 0.000 description 4
238000013461 design Methods 0.000 description 4
-1 for example Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000000693 micelle Substances 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000007900 aqueous suspension Substances 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000007909 solid dosage form Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
206010061902 Pancreatic neoplasm Diseases 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
238000010100 freeform fabrication Methods 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000010437 gem Substances 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000011068 loading method Methods 0.000 description 2
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
201000002528 pancreatic cancer Diseases 0.000 description 2
208000008443 pancreatic carcinoma Diseases 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920005606 polypropylene copolymer Polymers 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000002002 slurry Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
238000009475 tablet pressing Methods 0.000 description 2
239000003440 toxic substance Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
229920002148 Gellan gum Polymers 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003457 anti-vomiting effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000010492 gellan gum Nutrition 0.000 description 1
239000000216 gellan gum Substances 0.000 description 1
229910001751 gemstone Inorganic materials 0.000 description 1
230000005484 gravity Effects 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
239000007887 hard shell capsule Substances 0.000 description 1
239000013056 hazardous product Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229960001855 mannitol Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000004081 narcotic agent Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
238000000110 selective laser sintering Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005495 thyroid hormone Substances 0.000 description 1
229940036555 thyroid hormone Drugs 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000011800 void material Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y10/00—Processes of additive manufacturing
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y80/00—Products made by additive manufacturing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Materials Engineering (AREA)
Manufacturing & Machinery (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AU2001263506A 2000-05-18 2001-05-18 Encapsulating a toxic core within a non-toxic region in an oral dosage form Abandoned AU2001263506A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US20589600P	2000-05-18	2000-05-18
US60205896		2000-05-18
PCT/US2001/040763 WO2001087272A2 (fr)	2000-05-18	2001-05-18	Procede et forme d'un dispositif d'administration de medicament, par exemple enrober un noyau toxique a l'interieur d'une zone non toxique en forme posologique orale

Publications (1)

Publication Number	Publication Date
AU2001263506A1 true AU2001263506A1 (en)	2001-11-26

Family

ID=22764098

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001263506A Abandoned AU2001263506A1 (en)	2000-05-18	2001-05-18	Encapsulating a toxic core within a non-toxic region in an oral dosage form

Country Status (9)

Country	Link
US (2)	US7276252B2 (fr)
EP (1)	EP1286663B1 (fr)
JP (2)	JP5178982B2 (fr)
AT (1)	ATE315930T1 (fr)
AU (1)	AU2001263506A1 (fr)
CA (1)	CA2408956C (fr)
DE (1)	DE60116758T2 (fr)
ES (1)	ES2257412T3 (fr)
WO (1)	WO2001087272A2 (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030118645A1 (en) *	1998-04-29	2003-06-26	Pather S. Indiran	Pharmaceutical compositions for rectal and vaginal administration
US6544555B2 (en)	2000-02-24	2003-04-08	Advancis Pharmaceutical Corp.	Antibiotic product, use and formulation thereof
US6565882B2 (en) *	2000-02-24	2003-05-20	Advancis Pharmaceutical Corp	Antibiotic composition with inhibitor
US6541014B2 (en) *	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
US20020068078A1 (en) *	2000-10-13	2002-06-06	Rudnic Edward M.	Antifungal product, use and formulation thereof
US6518330B2 (en) *	2001-02-13	2003-02-11	Board Of Trustees Of University Of Illinois	Multifunctional autonomically healing composite material
WO2003041690A2 (fr) *	2001-10-29	2003-05-22	Therics, Inc.	Impression ou distribution d'une suspension, de type impression tridimensionnelle de formes galeniques
WO2003037607A1 (fr) *	2001-10-29	2003-05-08	Therics, Inc.	Systeme et procede de compression uniaxiale d'un article tel qu'une forme posologique a impression tridimensionnelle
WO2003037244A2 (fr) *	2001-10-29	2003-05-08	Therics, Inc.	Systeme d'elaboration de formes pharmaceutiques a liberation controlee, du type forme pharmaceutique a profil de liberation d'ordre zero elaboree en impression tridimensionnelle
DE60323482D1 (de) *	2002-05-06	2008-10-23	Massachusetts Inst Technology	Diffusionskontrollierte arzneiform sowie herstellungsmethode mittels dreidimensionalem drucken
EP1648407A4 (fr)	2003-07-21	2011-08-31	Middlebrook Pharmaceuticals Inc	Produit antibiotique, utilisation et formulation correspondantes
JP2006528189A (ja) *	2003-07-21	2006-12-14	アドバンシスファーマスーティカルコーポレイション	抗生物質産物、その使用法および製剤
CA2533358C (fr) *	2003-07-21	2014-03-11	Advancis Pharmaceutical Corporation	Produit antibiotique, utilisation et formulation associees
WO2005016311A1 (fr) *	2003-08-11	2005-02-24	Advancis Pharmaceutical Corporation	Pastille robuste
US8062672B2 (en) *	2003-08-12	2011-11-22	Shionogi Inc.	Antibiotic product, use and formulation thereof
EP1658034A4 (fr) *	2003-08-29	2011-06-22	Middlebrook Pharmaceuticals Inc	Produit antibiotique, son utilisation et sa formulation
CA2538064C (fr) *	2003-09-15	2013-12-17	Advancis Pharmaceutical Corporation	Antibiotique, son utilisation et sa formulation
US20050087902A1 (en) *	2003-10-28	2005-04-28	Isaac Farr	Alginate-based materials, methods of application thereof, and systems for using the alginate-based materials
JP2007517039A (ja) *	2003-12-24	2007-06-28	アドバンシスファーマスーティカルコーポレイション	変性放出製剤の吸収増強
US7566747B2 (en) *	2004-05-07	2009-07-28	The Board Of Trustees Of The University Of Illinois	Wax particles for protection of activators, and multifunctional autonomically healing composite materials
US20060002594A1 (en) *	2004-06-09	2006-01-05	Clarke Allan J	Method for producing a pharmaceutical product
TWI547431B (zh) *	2004-06-09	2016-09-01	史密斯克萊美占公司	生產藥物之裝置及方法
WO2006004069A1 (fr) *	2004-07-01	2006-01-12	Ngk Insulators, Ltd.	Très petite capsule et sa méthode de production
JP2008505124A (ja) *	2004-07-02	2008-02-21	アドバンシスファーマスーティカルコーポレイション	パルス送達用錠剤
ES2555152T3 (es) *	2004-11-26	2015-12-29	Aprecia Pharmaceuticals Co.	Formas de dosificación impresas en tres dimensiones
US7829000B2 (en) *	2005-02-25	2010-11-09	Hewlett-Packard Development Company, L.P.	Core-shell solid freeform fabrication
US7612152B2 (en) *	2005-05-06	2009-11-03	The Board Of Trustees Of The University Of Illinois	Self-healing polymers
US7914776B2 (en) *	2005-10-07	2011-03-29	Adolor Corporation	Solid dispersions of opioid antagonists
US8778924B2 (en) *	2006-12-04	2014-07-15	Shionogi Inc.	Modified release amoxicillin products
US8357394B2 (en)	2005-12-08	2013-01-22	Shionogi Inc.	Compositions and methods for improved efficacy of penicillin-type antibiotics
EP1973972A2 (fr) *	2006-01-05	2008-10-01	The Board Of Trustees Of The University Of Illinois	Système de revêtement autorégénérant
GB0608402D0 (en) *	2006-04-28	2006-06-07	Diurnal Ltd	Thyroid treatment
US8299052B2 (en)	2006-05-05	2012-10-30	Shionogi Inc.	Pharmaceutical compositions and methods for improved bacterial eradication
US7569625B2 (en) *	2006-06-02	2009-08-04	The Board Of Trustees Of The University Of Illinois	Self-healing elastomer system
WO2008012542A2 (fr)	2006-07-25	2008-01-31	Lipoxen Technologies Limited	Dérivatisation d'érythropoïétine
US20080107725A1 (en) *	2006-10-13	2008-05-08	Albano Antonio A	Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
US20080299391A1 (en) *	2007-05-31	2008-12-04	White Scott R	Capsules, methods for making capsules, and self-healing composites including the same
WO2009007969A2 (fr) *	2007-07-09	2009-01-15	Colint Ltd.	Appareil d'hydratation portable
US20090181254A1 (en) *	2008-01-15	2009-07-16	The Board Of Trustees Of The University Of Illinois	Multi-capsule system and its use for encapsulating active agents
JP2011074015A (ja) *	2009-09-30	2011-04-14	Tomita Pharmaceutical Co Ltd	固形製剤及びその製造方法
DE102010051743B4 (de)	2010-11-19	2022-09-01	C. Miethke Gmbh & Co. Kg	Programmierbares Hydrocephalusventil
ES2671926T3 (es) *	2011-05-25	2018-06-11	Taiho Pharmaceutical Co., Ltd.	Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
US9381154B2 (en) *	2011-06-09	2016-07-05	Xerox Corporation	Direct inkjet fabrication of drug delivery devices
US8414654B1 (en) *	2011-11-23	2013-04-09	Amendia, Inc.	Bone implants and method of manufacture
CN102551927A (zh) *	2011-11-29	2012-07-11	上海大学	嵌入式分级释药三维支架及其制备方法
US8888480B2 (en)	2012-09-05	2014-11-18	Aprecia Pharmaceuticals Company	Three-dimensional printing system and equipment assembly
AU2013313053B2 (en)	2012-09-05	2015-04-30	Aprecia Pharmaceuticals LLC	Three-dimensional printing system and equipment assembly
US20140099351A1 (en)	2012-10-04	2014-04-10	Axxia Pharmaceuticals, Llc	Process for making controlled release medical implant products
US9339489B2 (en)	2013-03-15	2016-05-17	Aprecia Pharmaceuticals Company	Rapid disperse dosage form containing levetiracetam
ES2761407T3 (es)	2013-03-15	2020-05-19	Aprecia Pharmaceuticals LLC	Forma de dosificación rápidamente dispersable de topiramato
EP3431141B1 (fr)	2013-03-15	2021-12-08	Aprecia Pharmaceuticals LLC	Procédé d'impression tridimensionnelle
ES2761265T3 (es) *	2013-03-15	2020-05-19	Aprecia Pharmaceuticals LLC	Forma de dosificación de oxcarbazepina rápidamente dispersable
EP3033188A4 (fr)	2013-08-16	2017-03-22	The Exone Company	Moules de coulée de métal imprimés tridimensionnels et leurs procédés de fabrication
JP2016540887A (ja)	2013-10-17	2016-12-28	ザエクスワンカンパニー	３次元印刷された熱間静水圧加圧成形用容器及びその製造方法
US11001048B2 (en)	2013-12-23	2021-05-11	The Exone Company	Method of three-dimensional printing using a multi-component build powder
ES2745763T3 (es)	2013-12-23	2020-03-03	The Exone Co	Métodos y sistemas para la impresión en tres dimensiones utilizando múltiples fluidos aglutinantes
US10188739B2 (en)	2014-02-27	2019-01-29	Xenetic Biosciences, Inc.	Compositions and methods for administering insulin or insulin-like protein to the brain
US20170120329A1 (en)	2014-05-29	2017-05-04	The Exone Company	Process for Making Nickel-Based Superalloy Articles by Three-Dimensional Printing
EP3169499A2 (fr)	2014-07-17	2017-05-24	The Exone Company	Procédés et appareils de durcissement d'articles imprimés en trois dimensions
US9854828B2 (en)	2014-09-29	2018-01-02	William Langeland	Method, system and apparatus for creating 3D-printed edible objects
EP3227109B1 (fr)	2014-12-03	2020-08-19	The Exone Company	Procédé de fabrication d'articles de carbone densifié par une impression en trois dimensions
US10363220B2 (en)	2015-06-03	2019-07-30	Triastek, Inc.	Compartmented pharmaceutical dosage forms
KR102570502B1 (ko)	2015-08-21	2023-08-25	아프레시아 파마슈티칼즈 엘엘씨	3차원 인쇄 시스템 및 장비 어셈블리
CN118975972A (zh)	2015-10-23	2024-11-19	林德拉治疗公司	用于治疗剂缓释的胃驻留系统及其使用方法
CN108697649A (zh)	2015-12-08	2018-10-23	林德拉有限公司	用于胃驻留系统的几何构型
JP6878417B2 (ja) *	2016-02-17	2021-05-26	トリアステックインコーポレイテッド	剤形およびそれらの使用
WO2017193099A1 (fr)	2016-05-05	2017-11-09	Xiaoling Li	Forme pharmaceutique à libération contrôlée
AU2017268840B2 (en)	2016-05-27	2022-02-10	Lyndra Therapeutics, Inc.	Materials architecture for gastric residence systems
US10765658B2 (en)	2016-06-22	2020-09-08	Mastix LLC	Oral compositions delivering therapeutically effective amounts of cannabinoids
GB201612853D0 (en) *	2016-07-25	2016-09-07	Univ Central Lancashire	Solid dosage form production
AU2017336154B2 (en)	2016-09-30	2023-11-09	Lyndra Therapeutics, Inc.	Gastric residence systems for sustained delivery of adamantane-class drugs
GB201620066D0 (en) *	2016-11-28	2017-01-11	Ucl Business Plc	Solid Pharmaceutical dosage formulations and processes
US12102721B2 (en)	2017-01-26	2024-10-01	Triastek, Inc.	Dosage forms of controlled release at specific gastrointestinal sites
US11602502B2 (en)	2017-02-24	2023-03-14	Hewlett-Packard Development Company, L.P.	Three-dimensional (3D) printing a pharmaceutical tablet
GR1009361B (el) *	2017-05-11	2018-09-17	Κωνσταντινος Ηλια Θεοδοσοπουλος	Συστημα παραγωγης μεσω τρισδιαστατης εκτυπωσης, δισκιων, κοκκιων και καψουλων
EP3635045A1 (fr)	2017-05-26	2020-04-15	Infinite Material Solutions, LLC	Compositions polymères hydrosolubles
TWI811221B (zh)	2017-06-09	2023-08-11	美商萊恩卓治療公司	具有釋放速率調節膜之胃的滯留系統
WO2019137200A1 (fr)	2018-01-09	2019-07-18	Triastek, Inc.	Formes posologiques pour médicament à usage oral comprenant une dose fixe de non-stimulant du tdah et de stimulant du tdah
US10350822B1 (en)	2018-01-09	2019-07-16	Triastek Inc.	Dosage forms with desired release profiles and methods of designing and making thereof
DE102018107585B3 (de) *	2018-03-29	2019-03-28	Universität Rostock	Vorrichtung zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen mit Wirkstoffdepots, sowie Verfahren zur Herstellung von 3D-gedruckten Wirkstofffreisetzungssystemen
IT201800004265A1 (it)	2018-04-06	2019-10-06		Apparato e metodo per la produzione automatizzata di forme di dosaggio personalizzabili.
CN112867482B (zh)	2018-10-15	2023-04-25	阿普雷奇亚制药有限责任公司	在包装内形成剂型的方法和系统
WO2020143864A1 (fr) *	2019-01-07	2020-07-16	Nuuvera Deutschland GmbH	Dispositif de mise en comprimés d'une composition de principes actifs pulvérulente, liquide, pâteuse, encapsulée ou granulaire
US11724486B2 (en)	2019-07-09	2023-08-15	Kyndryl, Inc.	Printing customized medication based on current user data and medical records of the user
GB201913972D0 (en)	2019-09-27	2019-11-13	Univ Ulster	Pharmaceutical Delivery Device and method of manufacture
CN116018131A (zh)	2020-06-26	2023-04-25	阿普雷奇亚制药有限责任公司	具有内腔的快速口腔分散片剂
WO2022089588A1 (fr)	2020-10-30	2022-05-05	南京三迭纪医药科技有限公司	Forme pharmaceutique à rétention gastrique
US12251208B2 (en)	2020-11-30	2025-03-18	International Business Machines Corporation	Time controlled medication
GB2608846A (en) *	2021-07-14	2023-01-18	Quay Pharmaceuticals Ltd	Method and apparatus for additive manufacturing

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2801203A (en) *	1951-03-22	1957-07-30	Byk Gulden Lomberg Chem Fab	X-ray method of digestive enzyme diagnosis using protected core of contrast agent
US4943579A (en) *	1987-10-06	1990-07-24	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Water soluble prodrugs of camptothecin
US5082669A (en)	1989-07-20	1992-01-21	Dainippon Pharmaceutical Co., Ltd.	Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5215989A (en)	1989-12-08	1993-06-01	Merck & Co., Inc.	Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
US5314696A (en) *	1991-06-27	1994-05-24	Paulos Manley A	Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
WO1994009762A1 (fr)	1992-11-05	1994-05-11	Merck & Co., Inc.	Dispositif d'administration de medicaments
US6280771B1 (en) *	1997-02-20	2001-08-28	Therics, Inc.	Dosage forms exhibiting multi-phasic release kinetics and methods of manufacture thereof
ZA949929B (en) *	1993-12-23	1995-08-23	Akzo Nobel Nv	Sugar-coated pharmaceutical dosage unit.
JPH07223970A (ja) *	1994-02-10	1995-08-22	Tanabe Seiyaku Co Ltd	消化管内適所放出製剤
EP0759303B1 (fr) *	1994-04-22	2002-10-16	Yamanouchi Pharmaceutical Co. Ltd.	Systeme de liberation de medicament specifique au colon
US5597829A (en) *	1994-05-09	1997-01-28	Bionumerik Pharmaceuticals, Inc.	Lactone stable formulation of camptothecin and methods for uses thereof
US5783212A (en) *	1996-02-02	1998-07-21	Temple University--of the Commonwealth System of Higher Education	Controlled release drug delivery system
WO1998036739A1 (fr)	1997-02-20	1998-08-27	Therics, Inc.	Formes galeniques presentant une cinetique de liberation a phases multiples et leurs procedes de preparation
US6046177A (en) *	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6294199B1 (en) *	1999-04-13	2001-09-25	Beecham Pharmaceuticals (Pte) Limited	Method of treating a bacterial infection comprising administering amoxycillin

2001
- 2001-05-18 CA CA2408956A patent/CA2408956C/fr not_active Expired - Fee Related
- 2001-05-18 JP JP2001583741A patent/JP5178982B2/ja not_active Expired - Fee Related
- 2001-05-18 DE DE60116758T patent/DE60116758T2/de not_active Expired - Lifetime
- 2001-05-18 ES ES01937808T patent/ES2257412T3/es not_active Expired - Lifetime
- 2001-05-18 AU AU2001263506A patent/AU2001263506A1/en not_active Abandoned
- 2001-05-18 WO PCT/US2001/040763 patent/WO2001087272A2/fr active IP Right Grant
- 2001-05-18 AT AT01937808T patent/ATE315930T1/de not_active IP Right Cessation
- 2001-05-18 US US09/861,480 patent/US7276252B2/en not_active Expired - Lifetime
- 2001-05-18 EP EP01937808A patent/EP1286663B1/fr not_active Expired - Lifetime
2005
- 2005-10-07 US US11/246,910 patent/US7875290B2/en not_active Expired - Fee Related
2012
- 2012-01-25 JP JP2012012834A patent/JP2012082224A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1286663B1 (fr)	2006-01-18
EP1286663A2 (fr)	2003-03-05
JP5178982B2 (ja)	2013-04-10
JP2003533470A (ja)	2003-11-11
DE60116758T2 (de)	2006-11-02
CA2408956C (fr)	2011-07-12
US7276252B2 (en)	2007-10-02
WO2001087272A3 (fr)	2002-04-18
ES2257412T3 (es)	2006-08-01
DE60116758D1 (de)	2006-04-06
US20060110443A1 (en)	2006-05-25
US20020015728A1 (en)	2002-02-07
WO2001087272A2 (fr)	2001-11-22
ATE315930T1 (de)	2006-02-15
CA2408956A1 (fr)	2001-11-22
US7875290B2 (en)	2011-01-25
JP2012082224A (ja)	2012-04-26

Publication	Publication Date	Title
EP1286663B1 (fr)	2006-01-18	Procede et forme d'un dispositif d'administration de medicament, par exemple enrober un noyau toxique a l'interieur d'une zone non toxique en forme posologique orale
US8728521B2 (en)	2014-05-20	Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
RU2428176C2 (ru)	2011-09-10	Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты
JP4789806B2 (ja)	2011-10-12	パントプラゾール多粒子処方
JP2005516020A (ja)	2005-06-02	ゼロ次持続放出剤形およびその製造方法
JPH0530804B2 (fr)	1993-05-11
PL174178B1 (pl)	1998-06-30	Preparat farmaceutyczny w postaci kapsułek zawierających kulki
CZ73196A3 (en)	1996-08-14	Novel balls for controlled release and pharmaceutical preparation in which said balls are contained
BG65306B1 (bg)	2008-01-31	Лекарствена форма с контролирано освобождаване, съдържаща галантамин
AU3492201A (en)	2001-08-20	Timed pulsatile drug delivery systems
JP2003533470A5 (fr)	2008-07-17
WO2001019901A2 (fr)	2001-03-22	Procede relatif a la formation de granules a revetement aqueux
KR20090065524A (ko)	2009-06-22	프로그래머블 부력전달기술
IE910852A1 (en)	1991-09-25	Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
KR20080026754A (ko)	2008-03-26	생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법
AU2014281702A1 (en)	2015-12-10	Delayed release cysteamine bead formulation
WO2003053420A1 (fr)	2003-07-03	Formulations de clindamycine a liberation prolongee, a impulsions multiples
WO2021191268A1 (fr)	2021-09-30	Forme posologique par voie orale à unités multiples à libération modifiée de succinate de doxylamine et chlorhydrate de pyridoxine et un procédé pour sa préparation
CA2654525A1 (fr)	2008-01-10	Compositions pharmaceutiques comprenant une combinaison de piperidinoalcanol et d'un decongestionnant
WO2006045152A1 (fr)	2006-05-04	Procede ameliore de preparation de comprimes
JP2003137771A (ja)	2003-05-14	難溶性薬物用医薬製剤
JP3343144B2 (ja)	2002-11-11	マイクロカプセル
Fulzele et al.	2013	Drug Delivery: Fast Dissolve Systems
CN1935124A (zh)	2007-03-28	磷酸川芎嗪缓释微丸及制备方法
AU2005299253A1 (en)	2006-05-04	Improved tabletting process